GSK Urges Regulatory Changes To Pull EU OTC Market From Doldrums
This article was originally published in The Pink Sheet Daily
Executive Summary
Issues including regulatory impediments, switch data requirements, rewards for innovation and exclusivity periods for switched products must be addressed urgently for the European OTC sector to remain attractive to pharma firms, GlaxoSmithKline execs say.